Molecular Partners AG, a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, and Orano Med, a pioneer in targeted alpha therapy, have announced a collaboration to develop novel Radio-DARPin therapeutics (RDTs) that use Orano Med’s 212Pb radioisotope as a payload to selectively kill cancer cells. Both companies will leverage their unique capabilities to enable rapid clinical development and agree to share costs for preclinical and clinical development for multiple oncology targets, the first of which is DLL3.
The partnership is based upon strong preclinical data supporting a highly differentiated profile for 212Pb-based RDTs. Besides strong binding to target proteins and selective delivery of radioactive payloads, these data have also indicated the ability of RDTs to minimize kidney damage often associated with protein-based radioligand therapies while maintaining high tumor uptake. This agreement represents the first co-development deal for Molecular Partners and Orano Med. Both companies are developing additional radioligand therapy candidates in partnership with other companies, with Molecular Partners having announced its first collaboration with Novartis in December 2021.
“Orano Med provides extensive expertise and a secure supply of a powerful, highly focused source of radiation for precision cancer treatment, expanding our RDT portfolio in new directions,” said Patrick Amstutz, Ph.D., CEO of Molecular Partners. “While we have been able to demonstrate the potent and highly selective targeting of tumor cells by DARPins, it is imperative that we align ourselves with our partners who have the scientific, technical and logistical expertise to develop, manufacture and supply radiotherapeutics. Having worked with the Orano Med team for many months, we are excited and confident in their expertise and capabilities, as well as by their ambition to co-develop molecules in the clinic. We look forward to working jointly to bring these RDT programs into the clinics as rapidly as possible.”
“We are extremely excited to start this collaboration with Molecular Partners and to unlock the full potential of their DARPin platform in the field of radioligand therapies. We have been impressed by the versatility of the DARPin platform and by their in-house expertise in optimizing DARPins for applications in targeted alpha therapies. This collaboration enables us to meet the 3 key success factors in this field: leveraging a safe, convenient, and potent radioactive payload, achieving effective vectorization, and mastering the intricacies of the supply chain. This collaboration will further diversify our targeting approach, which combines the unique properties of 212Pb and Orano Med’s unparalleled global manufacturing supply chain. It will expedite the development of 212Pb-based radiotherapies to bring new breakthrough solutions for patients living with cancer”, said Julien Dodet, CEO of Orano Med.
Under the terms of the co-development agreement, Molecular Partner’s previously disclosed RDT target DLL3 (delta-like ligand 3) will be included in the partnership with Orano Med. Expression of DLL3 is low in healthy tissue but significantly increased in certain tumor types, such as small-cell lung cancer, providing an opportunity for selective tumor-targeting. DLL3 will be exclusively developed by Molecular Partners and Orano Med as a RDT target. Molecular Partners will maintain the option to explore DLL3 for targeted therapy outside of the radiotherapy space.
Both companies commit to sharing the cost of preclinical and clinical development with additional commitments to supply of their respective materials. Additional agreements are being put in place for future development and commercialization of any potential programs that proceed into the clinical stage of development.
Also Read:
BioSkryb Genomics Partners with Research Instruments expanding reach in Singapore and SEA
Biocytogen Pharmaceuticals signs a License Agreement With Pheon Therapeutics
Heligenics announces precision genetics test for breast cancer therapeutics
